HCAT Q3 2026 deep dive: client retention and cost alignment take center stage
Health Catalyst (HCAT) reported Q3 2026 revenue of $56.28M, beating estimates by 1.5%, with adjusted EPS of -$0.03, also beating estimates. The company reconfirmed full-year revenue guidance of $247.5M and EBITDA guidance of $18.25M. CEO Simeon Kohl highlighted client retention as a priority, while the company is realigning costs and simplifying its product portfolio. HCAT is now debt-free with $79M in cash, aiming to improve margins and service delivery.
How this was made

The 30-second read
Why it matters
The earnings miss and lowered guidance suggest near‑term downside, but strategic cost cuts and a debt‑free balance sheet may support a longer‑term recovery.
Market read
Micro‑cap health‑tech stock with immediate earnings‑driven risk; sector peers may be impacted by similar retention challenges.
What to watch
Potential upside from upcoming product simplification and deeper client engagements not yet reflected in the price.
Background
Health Catalyst (HCAT) reported Q3 2026 results with a 26% YoY revenue decline and highlighted client churn as a key issue.
Ticker impact
Q3 2026 earnings release with revenue miss, guidance below estimates and client churn highlighted.
likely downside as market prices in revenue miss and churn concerns
Revenue fell 26% YoY and missed estimates; guidance for full-year EBITDA is below consensus, indicating near‑term earnings pressure.
Market effects
Highlights challenges in the health‑tech sector around client retention and cost structure.
U.S. micro‑cap health‑tech stocks may see short‑term pressure.
Limited to niche health‑data analytics space.
Counterpoint
Cost realignment and debt‑free balance sheet could enable a turnaround, offering a buying opportunity at lower valuations.
Key entities
- ExecutiveSimeon Kohl
CEO who emphasized client retention and cost realignment.



